Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company

Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison

Fineline Cube May 8, 2024

Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for...

Company

AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients

Fineline Cube May 8, 2024

AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd...

Company Deals

Siemens Healthineers AG Forges Expanded Partnership with Xi’an Daixing Hospital

Fineline Cube May 8, 2024

Germany’s Siemens Healthineers AG (ETR: SHL) has entered into an eight-year value partnership with Xi’an...

Company Drug

Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau

Fineline Cube May 8, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...

Company Drug

Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment

Fineline Cube May 8, 2024

China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...

Company Medical Device

Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization

Fineline Cube May 8, 2024

Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...

Company Deals

Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production

Fineline Cube May 8, 2024

Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...

Company Medical Device

Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval

Fineline Cube May 8, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...

Company Policy / Regulatory

Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences

Fineline Cube May 8, 2024

This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...

Company Drug

LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China

Fineline Cube May 8, 2024

Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...

Company Deals

Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion

Fineline Cube May 7, 2024

Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...

Company Drug

Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer

Fineline Cube May 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Drug

Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China

Fineline Cube May 7, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial

Fineline Cube May 7, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Drug

Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval

Fineline Cube May 7, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...

Company

Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development

Fineline Cube May 7, 2024

B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO)...

Policy / Regulatory

China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling

Fineline Cube May 7, 2024

In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...

Company Drug

Merus’s Zenocutuzumab Receives Priority Review Status from FDA for Lung and Pancreatic Cancer Indications

Fineline Cube May 7, 2024

Dutch biotechnology company Merus (NASDAQ: MRUS) has announced that the US Food and Drug Administration...

Policy / Regulatory

Lei Haichao Takes Over as Party Secretary of China’s National Health Commission

Fineline Cube May 7, 2024

The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...

Company Drug

Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China

Fineline Cube May 7, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...

Posts pagination

1 … 302 303 304 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.